CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of a loss of $1.15. This compares to earnings of $1.10 per share a year ago. These ...

Truist raised the firm’s price target on Crispr Therapeutics (CRSP) to $120 from $100 and keeps a Buy rating on the shares. The company’s Q4 ...

Barclays analyst Gena Wang raised the firm’s price target on Crispr Therapeutics (CRSP) to $56 from $55 and keeps an Equal Weight rating on the ...

Intellia Therapeutics Inc. overhyped its lung-disease therapy study despite inefficiencies and costliness of such viral-editing treatments, sending share prices down 15%, a proposed class action says.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.